The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...

Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies ...

The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin ...

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise ...

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

Roivant Sciences is hoping for a big year. Earlier this month, the company revealed positive data for an inflammatory bowel disease drug it’s developing with Pfizer, positioning it as a competitor to ...

Kalvista set a price of $16,720 per dose, which consists of two 600 milligram tablets of Ekterly, known scientifically as sebetralstat. A company spokesperson stated Kalvista “priced Ekterly ...

Biotechnology startup Orum Therapeutics has banked 145 billion Korean won, or about $100 million, to fuel development of medicines that merge elements of two popular drugmaking approaches. Orum on ...